NASDAQ:EDSA Edesa Biotech (EDSA) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free EDSA Stock Alerts $4.47 +0.16 (+3.71%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$4.46▼$4.6050-Day Range$4.06▼$5.6552-Week Range$2.46▼$8.61Volume2,358 shsAverage Volume12,194 shsMarket Capitalization$14.38 millionP/E RatioN/ADividend YieldN/APrice Target$39.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Edesa Biotech alerts: Email Address Edesa Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside772.5% Upside$39.00 Price TargetShort InterestHealthy0.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$20,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.32) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector492nd out of 907 stocksPharmaceutical Preparations Industry224th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingEdesa Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEdesa Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.65% of the float of Edesa Biotech has been sold short.Short Interest Ratio / Days to CoverEdesa Biotech has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edesa Biotech has recently decreased by 22.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdesa Biotech does not currently pay a dividend.Dividend GrowthEdesa Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EDSA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Edesa Biotech this week, compared to 0 articles on an average week.Search Interest3 people have searched for EDSA on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edesa Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.00% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.50% of the stock of Edesa Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Edesa Biotech are expected to grow in the coming year, from ($2.32) to ($1.67) per share.Price to Book Value per Share RatioEdesa Biotech has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here About Edesa Biotech Stock (NASDAQ:EDSA)Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Read More EDSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDSA Stock News HeadlinesMarch 26, 2024 | insidertrades.comInsider Buying: Edesa Biotech, Inc. (NASDAQ:EDSA) CEO Acquires 5,000 Shares of StockFebruary 15, 2024 | finance.yahoo.comEDSA: Development of EB05 in ARDS Continues…April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 14, 2024 | investing.comEdesa Biotech Inc (EDSA)February 11, 2024 | benzinga.comEdesa Biotech Stock (NASDAQ:EDSA) Earnings Dates and Earning CallsFebruary 9, 2024 | finance.yahoo.comEdesa Biotech Reports Fiscal 1st Quarter 2024 ResultsJanuary 2, 2024 | finance.yahoo.comEDSA: Updated Phase 3 Protocol for EB05 Trial Approved by Canadian Regulators…December 15, 2023 | finance.yahoo.comEdesa Biotech Reports Fiscal Year 2023 ResultsApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.December 1, 2023 | benzinga.comEdesa Biotech Stock (NASDAQ:EDSA) Dividends: History, Yield and DatesNovember 12, 2023 | morningstar.comEdesa Biotech Inc EDSANovember 2, 2023 | msn.comEdesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38October 26, 2023 | finance.yahoo.comEdesa Biotech to Present at Dermatology Drug Development SummitOctober 25, 2023 | finance.yahoo.comRegulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS DrugOctober 19, 2023 | finance.yahoo.comEDSA: Secures up to CAD$23 Million to Fund Development of EB05…October 12, 2023 | msn.comWhy Is Infectious Disease Player Edesa Biotech Stock Soaring Today?October 12, 2023 | finance.yahoo.comEdesa Biotech to Receive Up To C$23 Million in Funding from Federal GovernmentOctober 12, 2023 | finance.yahoo.comEdesa Biotech Secures $10 Million Credit Facility with Company FounderOctober 11, 2023 | seekingalpha.comEdesa Biotech falls after 1-for-7 reverse stock split announcementOctober 10, 2023 | marketwatch.comEdesa Biotech Falls to 52-Week Low on Reverse Split NewsOctober 10, 2023 | finance.yahoo.comEdesa Biotech Announces One-for-Seven Reverse Share SplitSeptember 28, 2023 | finance.yahoo.comEdesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug CandidateAugust 16, 2023 | finance.yahoo.comEDSA: EB05 Inhibits Inflammation Initiated by Multiple Pathogens In Vitro…August 15, 2023 | msn.comHC Wainwright & Co. Maintains Edesa Biotech (EDSA) Buy RecommendationAugust 9, 2023 | finance.yahoo.comEdesa Biotech Reports Fiscal Third Quarter 2023 ResultsJuly 27, 2023 | finance.yahoo.comEdesa Biotech to Participate in Upcoming Canaccord Genuity Growth ConferenceJune 28, 2023 | msn.comEdesa Biotech's COVID-19 Candidate Restraints Inflammation From Influenza, Other Pathogens In Preclinical StudiesSee More Headlines Receive EDSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/09/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EDSA CUSIPN/A CIK1540159 Webwww.edesabiotech.com Phone(289) 800-9600Fax805-488-2889Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$39.00 High Stock Price Target$57.00 Low Stock Price Target$21.00 Potential Upside/Downside+770.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.78% Return on Assets-83.85% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.34 per share Price / Book1.91Miscellaneous Outstanding Shares3,220,000Free Float2,412,000Market Cap$14.43 million OptionableNot Optionable Beta0.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Pardeep Nijhawan FRCPC (Age 53)M.D., CEO, Company Secretary & Director Comp: $475.33kDr. Michael J. Brooks M.B.A. (Age 46)Ph.D., President Comp: $439.27kKey CompetitorsABVC BioPharmaNASDAQ:ABVCTraws PharmaNASDAQ:TRAWNeuroBo PharmaceuticalsNASDAQ:NRBOAytu BioPharmaNASDAQ:AYTUKiora PharmaceuticalsNASDAQ:KPRXView All CompetitorsInsidersPardeep NijhawanBought 5,000 shares on 3/25/2024Total: $20,000.00 ($4.00/share)View All Insider Transactions EDSA Stock Analysis - Frequently Asked Questions Should I buy or sell Edesa Biotech stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EDSA shares. View EDSA analyst ratings or view top-rated stocks. What is Edesa Biotech's stock price target for 2024? 2 Wall Street research analysts have issued twelve-month price targets for Edesa Biotech's shares. Their EDSA share price targets range from $21.00 to $57.00. On average, they predict the company's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 772.5% from the stock's current price. View analysts price targets for EDSA or view top-rated stocks among Wall Street analysts. How have EDSA shares performed in 2024? Edesa Biotech's stock was trading at $4.57 at the start of the year. Since then, EDSA shares have decreased by 2.2% and is now trading at $4.47. View the best growth stocks for 2024 here. Are investors shorting Edesa Biotech? Edesa Biotech saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 15,200 shares, a decline of 22.1% from the March 31st total of 19,500 shares. Based on an average trading volume of 12,700 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.7% of the shares of the company are short sold. View Edesa Biotech's Short Interest. When is Edesa Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EDSA earnings forecast. How were Edesa Biotech's earnings last quarter? Edesa Biotech, Inc. (NASDAQ:EDSA) announced its earnings results on Friday, February, 9th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.67. When did Edesa Biotech's stock split? Edesa Biotech shares reverse split on Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Edesa Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), AT&T (T) and Amarin (AMRN). How do I buy shares of Edesa Biotech? Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EDSA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
